# Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

> **NCT07220629** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NodThera Limited** · enrollment: 82 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** NT-0796
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07220629
- **Lead sponsor:** NodThera Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-02
- **Primary completion:** 2026-08-21
- **Final completion:** 2026-08-21
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07220629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07220629, "Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07220629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*